BofA raised the firm’s price target on HashiCorp to $28 from $24 and keeps a Neutral rating on the shares. Q4 results and outlook exceeded “relatively low expectations,” but Q4 growth metrics were “underwhelming,” the analyst tells investors. However, the leading indicators for growth suggest the model is perhaps bottoming and new initiatives could reinvigorate growth, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCP:
- HashiCorp Announces Fourth Quarter and Fiscal Year 2024 Financial Results
- HCP Upcoming Earnings Report: What to Expect?
- Moderna downgraded, Gap upgraded: Wall Street’s top analyst calls
- HashiCorp upgraded to Overweight from Equal Weight at Morgan Stanley
- HashiCorp to announce fourth quarter and fiscal year 2024 financial results Mar. 5, 2024
